INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2026

Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2026								December 31, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,797)	$	—	$	1,923	$	10,720	$	(8,448)	$	—	$	2,272
Intangible asset – axicabtagene ciloleucel	7,110		(3,330)		—		3,780		7,110		(3,127)		—		3,983
Intangible asset – Trodelvy	11,730		(4,704)		—		7,026		11,730		(4,164)		—		7,566
Intangible asset – Hepcludex(1)	1,395		(462)		—		933		845		(415)		—		430
Other	1,458		(1,087)		—		372		1,483		(1,056)		—		428
Total finite-lived assets	32,413		(18,382)		—		14,032		31,888		(17,211)		—		14,678
Indefinite-lived assets – IPR&D(1)(2)	—		—		—		—		2,300		—		—		2,300
Total intangible assets	$	32,413	$	(18,382)	$	—	$	14,032	$	34,188	$	(17,211)	$	—	$	16,978

_______________________________

(1) In May 2026, FDA granted accelerated approval of Hepcludex (bulevirtide) for treatment of adults living with chronic hepatitis delta virus infection. Accordingly, the related IPR&D intangible asset of $550 million was reclassified to finite-lived assets in the second quarter of 2026.

(2) During the second quarter of 2026, we recorded an impairment for the remaining $1.75 billion IPR&D intangible asset balance related to sacituzumab govitecan-hziy (“SG”) for NSCLC. See “2026 Impairment” below.

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2026								December 31, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,797)	$	—	$	1,923	$	10,720	$	(8,448)	$	—	$	2,272
Intangible asset – axicabtagene ciloleucel	7,110		(3,330)		—		3,780		7,110		(3,127)		—		3,983
Intangible asset – Trodelvy	11,730		(4,704)		—		7,026		11,730		(4,164)		—		7,566
Intangible asset – Hepcludex(1)	1,395		(462)		—		933		845		(415)		—		430
Other	1,458		(1,087)		—		372		1,483		(1,056)		—		428
Total finite-lived assets	32,413		(18,382)		—		14,032		31,888		(17,211)		—		14,678
Indefinite-lived assets – IPR&D(1)(2)	—		—		—		—		2,300		—		—		2,300
Total intangible assets	$	32,413	$	(18,382)	$	—	$	14,032	$	34,188	$	(17,211)	$	—	$	16,978

_______________________________